Multiplex Immunofluorescence (mIF): Immunohistochemistry (IHC) Analytical Validation (DFCI)
BRD ID: 3,264
Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 229
Description
This assay analytical validation and performance report describes the methods used to validate an automated multiplex immunohistochemical (IHC) staining procedure for the Bond Max instrument to assess AE1/AE3, SOX10, CD3, CD8, CD4, CD31, Foxp3, CD68, CD163, PD-1, and PD-L1 immunostaining in formalin-fixed, paraffin-embedded (FFPE) specimens that includes melanoma, colorectal, head and neck, lung, Hodgkin lymphoma, tonsil, breast, glioblastoma, and pancreas specimens. The document also presents data that supports the reported accuracy, precision, analytical sensitivity and specificity, reportable range, and quality control procedure for each antigen. It is used by the Cancer Immune Monitoring and Analysis Center (CIMAC) at Dana Farber Cancer Institute (DFCI). It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network); https://dctd.cancer.gov/research/networks/precision-medicine-oncology/cimac-cidc).
Documents for Download
Analytical report_IHC_080718_DFCI_508_Final.pdf [Size: 271 KB]Biospecimens
- Tissue - General
- Tissue - Skin
- Tissue - Colorectal
- Tissue - Lung
- Tissue - Lymph Node
- Tissue - Tonsil
- Tissue - Brain
- Tissue - Breast
- Tissue - Pancreas
Diagnoses
- Not specified
- Neoplastic
Topics
- Platform-specific Methodology
Associated SOP Compendiums
- Platform-specific Methodology